Chris Senyek, Wolfe Research chief investment strategist, joins CNBC's 'Squawk on the Street' to discuss market outlooks, ...

If Trump actually fires Powell, expect chaos. That’s the blunt warning from Wall Street analysts, legal professionals, and ...

Former deputy Treasury Secretary Roger Altman said he did not think Jerome Powell would agree to leave if the president asked ...

Wolfe Research reaffirmed its ‘Outperform’ rating on UnitedHealth Group but cut its price target to $330 from $363, citing ongoing medical billing pressures. The firm highlighted that UnitedHealth’s ...

Fintel reports that on July 15, 2025, Wolfe Research downgraded their outlook for Realty Income (NYSE:O) from Outperform to ...

Centene Corporation (NYSE:CNC) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On July 2, Wolfe ...

Shares of MongoDB (MDB) rose about 2% on Wednesday after Wolfe Research began coverage on the database software company with ...

Overall, Wolfe favors a mix of growth and value as the second half of 2025 begins. Related articles Wolfe Research refreshes high-conviction ideas heading into H2 ...

Wolfe Research bumped its price target on Samsara (NYSE: IOT) to $45 from $41 in early June, keeping its Outperform rating in place.

The research firm reiterated the company’s solid position amid the “TTR craze” while also echoing its commercial execution strategy. Wolfe Research Initiates Coverage of BridgeBio Pharma ...

Investing.com -- Wolfe Research upgraded the M&A Independent sector to Market Weight from Underweight in a note Wednesday, citing a combination of stock underperformance and early signs of ...

Fintel reports that on May 13, 2025, Wolfe Research upgraded their outlook for Insulet (BMV:PODD) from Peer Perform to Outperform.